QEEG changes during switch from depression to hypomania/mania: a case report.
BACKGROUND
QEEG cordance and low-resolution electromagnetic tomography (LORETA) are relatively new applications of QEEG. Four small-scale studies have shown that decreases of QEEG prefrontal theta cordance after the first week on new antidepressants predict clinical response to treatment in patients with unipolar depression.


METHODS
We calculated prefrontal theta cordance and changes in 3D distribution of brain electrical activity using LORETA in the case of a 54-year old man experiencing his third depressive episode.


RESULTS
We did not detect a decrease of prefrontal theta cordance after one week of new treatment and the patient did not respond to this therapy after four weeks. However, we observed a decrease of prefrontal theta cordance after the first week of clomipramine therapy. Manic symptoms emerged after two weeks of clomipramine treatment. A decrease of prefrontal theta cordance preceded the clomipramine induced switch to hypomania during the next episode of depression also. LORETA before and during clomipramine therapies detected a significant increase of theta in the right postcentralis gyrus in the parietal lobe, and a borderline increase of alfa2 in the right middle frontal gyrus.


CONCLUSIONS
In a patient with bipolar spectrum disorder we found that a treefold change in theta prefrontal cordance preceded mood changes in a similar way as in patients with unipolar depression. We speculate that the changes detected by LORETA can attributed to the anticholinergic activity of clomipramine and the specific effects of a mood switch. Our data suggest that the new applications of QEEG can be sensitive to mood changes and have potential in bipolar disorder research.
Kopecek
Miloslav
M
Prague Psychiatric Centre; 3rd Faculty of Medicine, Charles University, Prague, Czech Republic. kopecek@pcp.lf3.cuni.cz
Tislerova
Barbora
B
Sos
Peter
P
Bares
Martin
M
Novak
Tomas
T
Krajca
Vladimir
V
Brunovsky
Martin
M
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D001921:Brain / Q000473:pathology; D002997:Clomipramine / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D004569:Electroencephalography; D006801:Humans; D015225:Magnetoencephalography; D008297:Male; D008875:Middle Aged; D010296:Parietal Lobe / Q000502:physiology; D011955:Receptors, Drug / Q000187:drug effects; D013826:Theta Rhythm
D000929:Antidepressive Agents, Tricyclic; D011955:Receptors, Drug; D002997:Clomipramine